Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.

Adult Clinical Trials

Brain/CNS

Protocol Alliance A071601
Cancer Type: CRANIOPHARYNGIOMAS
Fast Facts

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG BN007
Cancer Type: Unmethylated Glioblastoma
Fast Facts

A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

Protocol Alliance A071702
Cancer Type: Recurrent Glioblastoma
Fast Facts

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol N0577
Cancer Type: Codeleted Anaplastic Glioma
Fast Facts

Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A071401
Cancer Type: MENINGIOMAS WITH SMO/AKT/NF2 MUTATIONS
Fast Facts

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations

Protocol NRG BN003
Cancer Type: MENINGIOMA
Fast Facts

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A071701
Cancer Type: Brain metastases
Fast Facts

Genomically-Guided Treatment Trial in Brain Metastases

Protocol Alliance A071801
Cancer Type: Metastatic Brain Disease
Fast Facts

Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

Please check out the rare protocol list to locate other studies within this disease site.

Protocol WF 1801
Cancer Type: Cancer Control
Fast Facts

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Please check out the rare protocol list to locate other studies within this disease site.

Breast

Protocol AFT-25 COMET
Cancer Type: Low Risk DCIS
Fast Facts

Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial

 

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA1181
Cancer Type: Neoadjuvant Breast
Fast Facts

Preoperative THP and postoperative HP in patients who achieve a pathologic complete response

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1706
Cancer Type: Inflammatory Breast Cancer

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Please check out the rare protocol list to locate other studies within this disease site.

Protocol CCTG MA.39 Adjuvant
Cancer Type: LOW RISK NODE POSITIVE BREAST CANCER
Fast Facts

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

Protocol NRG BR003 Adjuvant
Cancer Type: Triple-Negative Invasive Breast Cancer
Fast Facts

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Protocol NRG BR007
Cancer Type: Stage 1, Hormone Sensitive Her2 negative
Fast Facts

Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive HER2-Negative, Oncotype Recurrence Score < 18 Breast Cancer (DEBRA) De-Escalation of Breast Radiation

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG BR002
Cancer Type: Newly Oligometastatic Breast Cancer
Fast Facts

A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

Protocol NRG-BR004
Cancer Type: Metastatic Breast Cancer
Fast Facts

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Please check out the rare protocol list to locate other studies within this disease site.

Protocol PDM 9846
Cancer Type: Tissue Procurement
Fast Facts

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A011202 Adjuvant
Cancer Type: Breast Cancer
Fast Facts

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Protocol Alliance A211601
Cancer Type: ABC Companion
Fast Facts

Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502

Protocol EAZ171
Cancer Type: peripheral neuropathy in African American women
Fast Facts

Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women

Protocol SWOG S1501 CC cardiac tox
Cancer Type: METASTATIC HER-2+ BREAST CANCER
Fast Facts

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III

Protocol SWOG S1703
Cancer Type: METASTATIC BREAST CANCER
Fast Facts

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer

Protocol SWOG S1714
Cancer Type: Multiple Cancer control
Fast Facts

A Prospective Observational Cohort Study to Develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients

Protocol URCC 16070 CC nausea
Cancer Type: Cancer Control
Fast Facts

Treatment of Refractory Nausea

Protocol URCC 18007
Cancer Type: Cancer-Related Fatigue
Fast Facts

Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue

Protocol URCC 19085
Cancer Type: Cancer Control
Fast Facts

Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy-Induced Peripheral Neuropathy: A Phase II Clinical Trial

Protocol Alliance A191901
Cancer Type: Cancer Control
Fast Facts

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

Protocol Alliance A231901CD
Cancer Type: CCDR
Fast Facts

IMPROVING PATIENT-CENTERED COMMUNICATION IN BREAST CANCER: A RCT OF A SHARED DECISION ENGAGEMENT SYSTEM (SHARES)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA1151 (TMIST)
Cancer Type: Screening
Fast Facts

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Please check out the rare protocol list to locate other studies within this disease site.

Cancer Care Delivery (CCDR)

Protocol Alliance A231901CD
Cancer Type: CCDR
Fast Facts

IMPROVING PATIENT-CENTERED COMMUNICATION IN BREAST CANCER: A RCT OF A SHARED DECISION ENGAGEMENT SYSTEM (SHARES)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG CC007CD
Cancer Type: Prostate Cancer
Fast Facts

Increasing the Dose of Survivorship Care Planning In Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy

Protocol Alliance A231601CD
Cancer Type: CCDR
Fast Facts

Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)

Please check out the rare protocol list to locate other studies within this disease site.

Cancer Control

Protocol PDM 9846
Cancer Type: Tissue Procurement
Fast Facts

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol WF 1801
Cancer Type: Cancer Control
Fast Facts

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A011202 Adjuvant
Cancer Type: Breast Cancer
Fast Facts

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Protocol Alliance A211601
Cancer Type: ABC Companion
Fast Facts

Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502

Protocol EAZ171
Cancer Type: peripheral neuropathy in African American women
Fast Facts

Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women

Protocol SWOG S1501 CC cardiac tox
Cancer Type: METASTATIC HER-2+ BREAST CANCER
Fast Facts

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III

Protocol SWOG S1703
Cancer Type: METASTATIC BREAST CANCER
Fast Facts

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer

Protocol URCC 16070 CC nausea
Cancer Type: Cancer Control
Fast Facts

Treatment of Refractory Nausea

Protocol URCC 18007
Cancer Type: Cancer-Related Fatigue
Fast Facts

Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue

Protocol URCC 19085
Cancer Type: Cancer Control
Fast Facts

Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy-Induced Peripheral Neuropathy: A Phase II Clinical Trial

Protocol SWOG S1904
Cancer Type: ATYPICAL HYPERPLASIA OR LOBULAR CARCINOMA IN SITU
Fast Facts

CLUSTER RANDOMIZED CONTROLLED TRIAL OF PATIENT AND PROVIDER DECISION SUPPORT TO INCREASE CHEMOPREVENTION INFORMED CHOICE AMONG WOMEN WITH
ATYPICAL HYPERPLASIA OR LOBULAR CARCINOMA IN SITU - MAKING INFORMED CHOICES ON INCORPORATING CHEMOPREVENTION INTO CARE (MiCHOICE)

Protocol Alliance A191901
Cancer Type: Cancer Control
Fast Facts

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S0820
Cancer Type: Colorectal
Fast Facts

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)

Protocol URCC 16092
Cancer Type: Cognitive Impairment in Colorectal Cancer
Fast Facts

Phase II Study of Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy

Protocol WF 1806
Cancer Type: Cancer Control
Fast Facts

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study

Please check out the rare protocol list to locate other studies within this disease site.

Protocol WF 1802
Cancer Type: Prostate Cancer
Fast Facts

Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG CC003
Cancer Type: SCLC
Fast Facts

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

Protocol EAQ172
Cancer Type: Pneumonitis
Fast Facts

Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1714
Cancer Type: Multiple Cancer control
Fast Facts

A Prospective Observational Cohort Study to Develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA1151 (TMIST)
Cancer Type: Screening
Fast Facts

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Protocol EA2185
Cancer Type: Pancreatic Cyst Surveillance
Fast Facts

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

Protocol DCP-001
Cancer Type: Multisite - Screening

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Protocol NCI COVID
Cancer Type: COVID 19 registry
Fast Facts

(NCICOVID) NCI COVID-19 in Cancer Patients Study (N-CCaPS):  A Longitudinal Natural History Study

Please check out the rare protocol list to locate other studies within this disease site.

Endocrine/Neuroendocrine

Protocol Alliance A021602
Cancer Type: Neuroendocrine
Fast Facts

RANDOMIZED, DOUBLE-BLINDED PHASE III STUDY OF CABOZANTINIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS AFTER PROGRESSION ON PRIOR THERAPY (CABINET)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A021804
Cancer Type: ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

Please check out the rare protocol list to locate other studies within this disease site.

Gastrointestinal

Protocol SWOG S2001
Cancer Type: Metastatic Pancreatic
Fast Facts

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations.

Protocol EA2186
Cancer Type: Metastatic Pancreatic
Fast Facts

A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)

Protocol Alliance A021806
Cancer Type: RESECTABLE PANCREATIC CANCER
Fast Facts

A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1922
Cancer Type: Small bowel Adenocarcinoma

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A021502
Cancer Type: Colon Cancer
Fast Facts

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer)

Protocol NRG GI005
Cancer Type: Stage IIA Colon Cancer
Fast Facts

Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A021703
Cancer Type: metastatic colorectal cancer
Fast Facts

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Protocol NRG GI004
Cancer Type: Colorectal Cancer
Fast Facts

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Protocol SWOG S1613
Cancer Type: Advanced/Metastatic Colorectal Cancer
Fast Facts

A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA2182
Cancer Type: Early Stage Anal Squamous Cell Carcinoma
Fast Facts

A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)

Protocol EA2176
Cancer Type: treatment-naïve metastatic anal cancer
Fast Facts

A Phase III Study of Immune checkpoint inhibition with chemotherapy in treatment-naïve metastatic anal cancer patients

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA2187
Cancer Type: Advanced Intrahepatic Cholangiocarinoma
Fast Facts

A Phase II Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma

Protocol EA2197
Cancer Type: Incidental Gallbladder Cancer
Fast Facts

Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN)- A Randomized Phase II/III Trial

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA2183
Cancer Type: Esophageal and Gastric Adenocarcinoma
Fast Facts

A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic Esophageal and Gastric Adenocarcinoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol PDM 9846
Cancer Type: Tissue Procurement
Fast Facts

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S0820
Cancer Type: Colorectal
Fast Facts

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)

Protocol WF 1806
Cancer Type: Cancer Control
Fast Facts

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study

Protocol URCC 16092
Cancer Type: Cognitive Impairment in Colorectal Cancer
Fast Facts

Phase II Study of Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA2185
Cancer Type: Pancreatic Cyst Surveillance
Fast Facts

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

Please check out the rare protocol list to locate other studies within this disease site.

Genitourinary

Protocol Alliance A031702
Cancer Type: rare genitourinary tumors

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG GU002
Cancer Type: Prostate
Fast Facts

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel

Protocol NRG GU005
Cancer Type: Prostate Cancer
Fast Facts

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

Protocol SWOG S1802
Cancer Type: Metastatic Prostate Cancer
Fast Facts

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Protocol EA8171
Cancer Type: Prostate Cancer
Fast Facts

Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A031704
Cancer Type: METASTATIC UNTREATED RENAL CELL
Fast Facts

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell Cancer [PDIGREE]

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A031803
Cancer Type: BCG-Unresponsive Non Muscle Invasive Bladder
Fast Facts

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Protocol SWOG S1806
Cancer Type: Bladder Cancer
Fast Facts

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer 

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A031102
Cancer Type: Germ Cell Tumor
Fast Facts

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

Protocol SWOG S1823
Cancer Type: Newly Diagnosed Germ Cell Tumors
Fast Facts

A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Protocol WF 1802
Cancer Type: Prostate Cancer
Fast Facts

Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG CC007CD
Cancer Type: Prostate Cancer
Fast Facts

Increasing the Dose of Survivorship Care Planning In Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy

Please check out the rare protocol list to locate other studies within this disease site.

Germ Cell

Protocol Alliance A031102
Cancer Type: Germ Cell Tumor
Fast Facts

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

Protocol SWOG S1823
Cancer Type: Newly Diagnosed Germ Cell Tumors
Fast Facts

A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Gynecologic

Protocol NRG GY019
Cancer Type: Carcinoma of the Ovary or Peritoneum
Fast Facts

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Protocol NRG CC008
Cancer Type: Ovarian Cancer Among BRCA1 Carriers
Fast Facts

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk] 

Protocol NRG GY009
Cancer Type: Platinum Resistant Ovarian Cancer
Fast Facts

A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer

Please check out the rare protocol list to locate other studies within this disease site.

Protocol GOG 0263
Cancer Type: Stage I/IIA Cervical Cancer

Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)

Protocol NRG GY006
Cancer Type: GYN-newly diagnosed, bulky stage
Fast Facts

A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

Protocol RTOG 0724
Cancer Type: Cervical Carcinoma

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG GY018
Cancer Type: ENDOMETRIAL CANCER
Fast Facts

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1714
Cancer Type: Multiple Cancer control
Fast Facts

A Prospective Observational Cohort Study to Develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients

Please check out the rare protocol list to locate other studies within this disease site.

Head and Neck

Protocol NRG HN001
Cancer Type: Nasopharyngeal Carcinoma

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1701
Cancer Type: Thymic Carcinoma

A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA3132
Cancer Type: Head and Neck
Fast Facts

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing    

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG HN007
Cancer Type: NASOPHARYNGEAL CARCINOMA

AN OPEN-LABEL, PHASE III STUDY OF PLATINUM-GEMCITABINE WITH OR WITHOUT NIVOLUMAB IN THE FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA3161
Cancer Type: HPV Positive OPCA
Fast Facts

A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA

Protocol NRG HN004
Cancer Type: Locoregionally Advanced Head and Neck Cancer

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin

Protocol EA3163
Cancer Type: Nasal and Paranasal Sinus Squamous Cell Carcinoma

Phase II Randomized Trial of Neo-Adjuvant Chemo f/b Surgery and Post-Op Radiation vs Surgery and Post-Op Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

Protocol NRG HN005
Cancer Type: Oropharyngeal Cancer
Fast Facts

A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer

Protocol RTOG 1216
Cancer Type: Pathologic High-Risk Squamous Cell Cancer
Fast Facts

Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

Please check out the rare protocol list to locate other studies within this disease site.

Leukemia

Protocol Alliance A041501
Cancer Type: NEWLY DIAGNOSED PRECURSOR B-CELL ALL
Fast Facts

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Protocol SWOG S1318
Cancer Type: (Ph-) ALL
Fast Facts

A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A041701
Cancer Type: ACUTE MYELOID LEUKEMIA
Fast Facts

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A041702
Cancer Type: Chronic Lymphocytic Leukemia (CLL)
Fast Facts

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (> 70 YEARS OF AGE) with Chronic Lymphocytic Leukemia (CLL)

Protocol SWOG S1925
Cancer Type: CLL/SLL
Fast Facts

RANDOMIZED, PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1712
Cancer Type: Chronic Myeloid Leukemia (CML)
Fast Facts

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NHLBI-MDS
Cancer Type: Myelodysplastic Syndromes
Fast Facts

The National Myelodysplastic Syndromes (MDS) Study

Please check out the rare protocol list to locate other studies within this disease site.

Lung

Protocol NRG LU006
Cancer Type: MALIGNANT PLEURAL MESOTHELIOMA

PHASE III RANDOMIZED TRIAL OF PLEURECTOMY/DECORTICATION PLUS
CHEMOTHERAPY WITH ORWITHOUT ADJUVANT HEMITHORACIC
INTENSITY-MODULATED PLEURAL RADIATION THERAPY (IMPRINT)
FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol ECOG E4512
Cancer Type: Non-Small Cell Lung
Fast Facts

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

A substudy of ALCHEMIST A151216

Protocol EA5162
Cancer Type: Advanced NSCLC
Fast Facts

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

Protocol EA5163
Cancer Type: Non-Small Cell Lung Cancer (NSCLC)
Fast Facts

A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis

Protocol EA5181
Cancer Type: NSCLC
Fast Facts

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Protocol NRG LU002
Cancer Type: METASTATIC NON-SMALL CELL LUNG CANCER
Fast Facts

Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

Protocol SWOG S1400F
Cancer Type: Lung Cancer
Fast Facts

A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated ANTI-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study)

Protocol SWOG S1914
Cancer Type: Early Stage NSCLC
Fast Facts

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Protocol Alliance A081801
Cancer Type: resected NSCLC
Fast Facts

Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO

Protocol EA5191
Cancer Type: NSCLC
Fast Facts

 A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC

Protocol Alliance A171901
Cancer Type: Older Non-Small Lung Cancer
Fast Facts

Older Non-Small Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist’s/Patient’s Choice)

Protocol SWOG S1900E
Cancer Type: NS NSCLC
Fast Facts

A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG CC003
Cancer Type: SCLC
Fast Facts

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

Protocol NRG LU005
Cancer Type: Limited Stage Small Cell Lung Cancer
Fast Facts

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Protocol SWOG S1827
Cancer Type: Small Cell Lung
Fast Facts

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI):  A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Protocol NRG LU007
Cancer Type: ES-SCLC
Fast Facts

 RAndomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC:  RAPTOR trial

Protocol SWOG S1929
Cancer Type: ES-SCLC
Fast Facts

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol PDM 9846
Cancer Type: Tissue Procurement
Fast Facts

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1714
Cancer Type: Multiple Cancer control
Fast Facts

A Prospective Observational Cohort Study to Develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A151216
Cancer Type: Non-Small Cell Lung
Fast Facts

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Sub-Studies to ALCHEMIST: A081105,  E4512 and EA5142

Protocol LUNG MAP
Cancer Type: NSCLC
Fast Facts

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

Please check out the rare protocol list to locate other studies within this disease site.

Lymphoma

Protocol Alliance A051301
Cancer Type: Lymphoma
Fast Facts

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1925
Cancer Type: CLL/SLL
Fast Facts

RANDOMIZED, PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A051701
Cancer Type: Double-hit and double-expressing lymphomas
Fast Facts

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1608
Cancer Type: FOLLICULAR LYMPHOMA
Fast Facts

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA4181
Cancer Type: Untreated Mantle Cell lymphoma
Fast Facts

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <70 years old with Untreated Mantle Cell Lymphoma 

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1826
Cancer Type: ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA
Fast Facts

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Please check out the rare protocol list to locate other studies within this disease site.

Multisite

Protocol TAPUR
Cancer Type: Multisite
Fast Facts

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Protocol EAY131 - MATCH
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH)

Protocol EAY131 - MATCH Protocol A
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol A: EAY131-A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment

Protocol EAY131 - MATCH Protocol C1
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol C1: EAY131-C1: Crizotinib in Patients with Tumors with MET Amplification

Protocol EAY131 - MATCH Protocol C2
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol C2: EAY131-C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion

Protocol EAY131 - MATCH Protocol E
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol E: EAY131-E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR

Protocol EAY131 - MATCH Protocol J
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol J: EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ, and Non-Colorectal Cancers with HER2 Amplification

Protocol EAY131 - MATCH Protocol K2
Cancer Type: Molecular

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol K2: EAY131-K2: Phase II Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions.

Protocol EAY131 - MATCH Protocol L
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol L: EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations

Protocol EAY131 - MATCH Protocol M
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol M: EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations

Protocol EAY131 - MATCH Protocol T
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol T: EAY131-T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations

Protocol EAY131 - MATCH Protocol V
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol V: EAY131-V: Phase II Study of Sunitinib in Patients with Tumors with c-Kit Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)

Protocol EAY131 - MATCH Protocol Z1E
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1E: EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions

Protocol EAY131 - MATCH protocol Z1F
Cancer Type: Molecular

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1F: EAY131-Z1F: Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed)

Protocol EAY131 - MATCH Protocol Z1G
Cancer Type: Molecular

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1G: EAY131-Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result

Protocol EAY131 - MATCH protocol Z1L
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol Z1L: EAY131-Z1L: Phase II Study of BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations

Protocol EAY131 - MATCH Protocol Z1H
Cancer Type: Molecular

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1H: EAY131-Z1H: Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC

Protocol SWOG S1609 DART
Cancer Type: Rare Tumors
Fast Facts

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Protocol EAY131 - MATCH Protocol Z1M
Cancer Type: Molecular
Fast Facts

Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients with LAG-3+ Tumors with Mismatch Repair Deficiency (MMR-d) after Progression on Anti-PD-1/PD-L1 Therapy

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A231601CD
Cancer Type: CCDR
Fast Facts

Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol DCP-001
Cancer Type: Multisite - Screening

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EAY131 - MATCH Protocol H
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol H: EAY131-H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer)

Please check out the rare protocol list to locate other studies within this disease site.

Myeloma

Protocol SWOG S1803
Cancer Type: Multiple Myeloma
Fast Facts

Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EAA181
Cancer Type: Newly diagnosed Multiple Myeloma
Fast Facts

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EAA173
Cancer Type: Smoldering Myeloma
Fast Facts

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Please check out the rare protocol list to locate other studies within this disease site.

Rare

Protocol Alliance A021804
Cancer Type: ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A091902
Cancer Type: ANGIOSARCOMA

A MULTICENTER PHASE II TRIAL OF PACLITAXEL WITH AND WITHOUT NIVOLUMAB IN TAXANE NAÏVE, AND NIVOLUMAB AND CABOZANTINIB IN TAXANE PRETREATED SUBJECTS WITH ANGIOSARCOMA

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1706
Cancer Type: Inflammatory Breast Cancer

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1922
Cancer Type: Small bowel Adenocarcinoma

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A031702
Cancer Type: rare genitourinary tumors

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA3163
Cancer Type: Nasal and Paranasal Sinus Squamous Cell Carcinoma

Phase II Randomized Trial of Neo-Adjuvant Chemo f/b Surgery and Post-Op Radiation vs Surgery and Post-Op Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

Protocol SWOG S1701
Cancer Type: Thymic Carcinoma

A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

Protocol NRG HN001
Cancer Type: Nasopharyngeal Carcinoma

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Protocol NRG HN004
Cancer Type: Locoregionally Advanced Head and Neck Cancer

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin

Protocol NRG HN007
Cancer Type: NASOPHARYNGEAL CARCINOMA

AN OPEN-LABEL, PHASE III STUDY OF PLATINUM-GEMCITABINE WITH OR WITHOUT NIVOLUMAB IN THE FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG LU006
Cancer Type: MALIGNANT PLEURAL MESOTHELIOMA

PHASE III RANDOMIZED TRIAL OF PLEURECTOMY/DECORTICATION PLUS
CHEMOTHERAPY WITH ORWITHOUT ADJUVANT HEMITHORACIC
INTENSITY-MODULATED PLEURAL RADIATION THERAPY (IMPRINT)
FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM)

Please check out the rare protocol list to locate other studies within this disease site.

Sarcoma

Protocol Alliance A091902
Cancer Type: ANGIOSARCOMA

A MULTICENTER PHASE II TRIAL OF PACLITAXEL WITH AND WITHOUT NIVOLUMAB IN TAXANE NAÏVE, AND NIVOLUMAB AND CABOZANTINIB IN TAXANE PRETREATED SUBJECTS WITH ANGIOSARCOMA

Please check out the rare protocol list to locate other studies within this disease site.

Skin

Protocol ECOG EA6141
Cancer Type: Melanoma-unresectable
Fast Facts

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

Protocol EA6134
Cancer Type: Melanoma
Fast Facts

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial

Protocol SWOG S1801
Cancer Type: Melanoma
Fast Facts

A Phase II Randomized Study of Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma

Protocol EA6192
Cancer Type: Advanced Melanoma
Fast Facts

A Phase II Study of Biomarker Driven Early Discontinuation of anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)

Protocol SWOG S2000
Cancer Type: Melanoma with Brain Metastases
Fast Facts

A Randomized Phase 2 Trial Of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab In Brafv600-Mutant Melanoma with Brain Metastases

Protocol EA6194
Cancer Type: Operable Melanoma
Fast Facts

Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA6174
Cancer Type: Merkel Cell Carcinoma
Fast Facts

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A091802
Cancer Type: Carcinoma of the Skin
Fast Facts

Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin 

Please check out the rare protocol list to locate other studies within this disease site.

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.